Twist Bioscience (TWST) Gross Margin (2017 - 2026)

Twist Bioscience (TWST) has reported Gross Margin for 10 consecutive years, with 52.76% the latest figure, recorded in Q2 2026.

• On a quarterly basis, Gross Margin fell 64.0% year-over-year to 52.76% in Q2 2026; TTM through Jun 2026 was 51.97%, a 272.0% increase from a year earlier, with the FY2025 full-year figure at 50.72%, up 811.0% from the prior year.
• Gross Margin was 52.76% for Q2 2026 at Twist Bioscience, up from 51.59% in the prior quarter.
• Over five years, Gross Margin peaked at 53.4% in Q2 2025 and troughed at 30.76% in Q1 2023.
• A 5-year average of 44.69% and a median of 45.01% in 2024 frame the typical range for Gross Margin.
• Across the five-year window, Gross Margin sank 1045 bps in 2023 and jumped 1025 bps in 2024, its largest moves.
• Over 5 years, Gross Margin stood at 45.72% in 2022, then declined by 11 bps to 40.51% in 2023, then climbed by 19 bps to 48.29% in 2024, then climbed by 8 bps to 52.05% in 2025, then advanced by 1 bps to 52.76% in 2026.
• The last three Gross Margin figures came in at 52.76% (Q2 2026), 51.59% (Q1 2026), and 52.05% (Q4 2025), per Business Quant data.